HOME >> BIOLOGY >> NEWS
HPV testing a cost-effective strategy for women with equivocal cervical screening results

A new study has found that using human papillomavirus (HPV) DNA testing to determine who should receive a cervical examination called colposcopy is a cost-effective management strategy for women with equivocal Pap test results known as ASCUS (atypical squamous cells of undetermined significance). The study appears in the January 18 issue of the Journal of the National Cancer Institute.

About 5% of all Pap tests result in a diagnosis of ASCUS; however, only about 10% of women with this abnormality actually have precancer or cancer. The ASCUS and low-grade squamous intraepithelial lesions (LSIL) triage study (ALTS) was launched in the late 1990s to determine the best management strategy for women with these Pap test abnormalities that would both maximize the detection of clinically significant disease and reduce the need for unnecessary office visits and procedures. Results from ALTS, published in 2003, found that referring only those women with a positive HPV test to colposcopy was as effective at detecting cervical precancer or cancer as referring all women to colposcopy.

Shalini L. Kulasingam, Ph.D., of the Duke Center for Clinical Health Policy Research, and colleagues used data from 3488 women with ASCUS enrolled in ALTS to study the cost-effectiveness of three management strategies studied in ALTS--immediate colposcopy, HPV DNA testing, or conservative management with repeat Pap tests at 6-month intervals.

They found that the cost associated with HPV DNA testing was acceptable given the number of precancers and cancers found by this strategy. HPV DNA testing was less costly and detected more cases of precancer than immediately sending all women to receive colposcopy. The least costly strategy was a single repeat Pap test with referral to colposcopy for only those women with a high grade Pap test result; however, this option detected the fewest cases of precancer. The researchers conclude that HPV DNA testing for women with ASCUS
'"/>

Contact: Ariel Whitworth
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
17-Jan-2006


Page: 1 2

Related biology news :

1. Modular leukemia drug shows promise in early testing
2. Rapid syphilis testing in Haiti will prevent congenital disease and stillbirths
3. XDx to present recent success with AlloMap molecular expression testing
4. Potential genetic testing for substance abuse raises hope, concern
5. U-M team: Genetic testing sheds light on degenerative eye disease
6. Antiretroviral resistance testing in HIV infected patients improves health and saves costs
7. Professors to develop hand-held pathogen testing device
8. Animal testing alternative has ticks trembling at the knees
9. New research to cut animal testing
10. New method of testing eggs for abnormalities could solve problems of embryo freezing
11. HPV testing finds precancerous lesions at a higher rate than conventional pap smears

Post Your Comments:
(Date:10/15/2014)... from strains of influenza virus increases with the latest ... complacent that the most substantial threats have been identified, ... arise when a new virus strain – against which ... in the human population. There have been five such ... which – the 1918 Spanish Flu – cost 50 ...
(Date:10/15/2014)... , Oct. 15, 2014 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market releases photos and ... Times Square on Monday October 13 th . ... David Tunnel and angel investor Mr. Chad A. Verdi ... CEO of NXT-ID thanked his investors and employees "for their work ...
(Date:10/14/2014)... (Oct. 14, 2014)—It,s been millions of years since ... team led by Ohio University scientists is breathing life ... airflow through dinosaur snouts. The research has important implications ... breathe but to enhance the sense of smell and ... animals," said Ohio University doctoral student Jason Bourke, lead ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
(Date:10/25/2014)... 2014 DuPont Pioneer and Perdue ... than double the acreage contracted for Plenish® high ... soybean crush facility in Salisbury, Md. The high ... target several markets including foodservice and food manufacturers ... , For the 2015 growing season, Perdue Agribusiness ...
(Date:10/25/2014)... October 24, 2014 SonaCare Medical, ... ultrasound (HIFU) technology, announced that its Board of ... Chief Executive Officer, President and member of the ... Carol will take-on expanded responsibilities within the company, ... well as overseeing commercialization, manufacturing and finance. ...
(Date:10/25/2014)... DALLAS and NEW YORK ... Biopharmaceuticals, Inc. (OTCQB: ACCPD), formerly Access Pharmaceuticals, Inc. ... critical areas, announced it has implemented a 1-for-50 ... the opening of trading on Friday, October 24, ... split-adjusted basis under new CUSIP number 72754H109 and ...
(Date:10/25/2014)... , October 24, 2014 ... http://www.researchandmarkets.com/research/t5t5pd/the_global_market ) has announced the addition of ... Graphene And Other 2-D Nanomaterials "  report ... http://photos.prnewswire.com/prnh/20130307/600769) , ,CNTs and graphene are the ... to man, with a performance-per-weight greater than ...
Breaking Biology Technology:DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 2DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 3DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 4SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 4
Cached News: